Quantitative proteomics analysis in small cell carcinoma of cervix reveals novel therapeutic targets

Haifeng Qiu1,2,3, Ning Su4, Jing Wang5

  • 1Department of Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Clinical Proteomics
|April 8, 2023
PubMed
Abstract

Insights

This study reveals key protein changes in small cell carcinoma of the cervix (SCCC), highlighting increased DNA replication and cell motility. These findings offer potential new targets for SCCC diagnosis and treatment.

Area of Science:

  • Proteomics
  • Oncology
  • Gynecologic Pathology

Background:

  • Small cell carcinoma of the cervix (SCCC) is a rare, aggressive cancer with limited treatment options.
  • Understanding SCCC's molecular basis is crucial for developing targeted therapies.
  • Current knowledge on SCCC origin and progression remains incomplete.

Purpose of the Study:

  • To investigate whole-protein expression profiles in SCCC.
  • To identify differentially expressed proteins (DEPs) associated with SCCC.
  • To provide evidence for precise diagnosis and targeted therapy in SCCC.

Main Methods:

  • Quantitative proteomics using data-independent acquisition mass spectrometry (DIA) on SCCC and normal cervix tissues.
  • Immunohistochemistry to validate expression of specific proteins (CDN2A, SYP).
  • Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses for DEPs.

Main Results:

  • 1311 DEPs identified in SCCC (780 up-regulated, 531 down-regulated).
  • Up-regulated DEPs linked to DNA replication and cell cycle, indicating high proliferation.
  • Down-regulated DEPs associated with extracellular matrix, complement/coagulation, and focal adhesion, potentially promoting metastasis.
  • Unique metabolic enzyme alterations identified in early-stage recurrent SCCC cases.

Conclusions:

  • Quantitative proteomics revealed significant protein alterations in SCCC, notably in DNA replication and cell motility.
  • Down-regulation of certain pathways may contribute to SCCC metastasis and treatment resistance.
  • A distinct metabolic profile in recurrent SCCC suggests potential for early detection and targeted intervention.